Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy
<a href="https://pixabay.com/users/frolicsomepl/">frolicsomepl</a> / Pixabay

Data Shows That Revolade is the Most Effective Second Line Immune Thrombocytopenia Therapy

According to a story from Market Screener, an analysis of real-world data (data gathered outside of the clinical setting) suggests that the drug eltrombopag, marketed as Revolade, offers substantial advantages…

Continue Reading

What are your thoughts on being a rare disease advocate? Share your stories, thoughts, and hopes with the Patient Worthy community!

Close Menu